Tolvaptan (BioDeep_00000399096)
natural product
代谢物信息卡片
Tolvaptan (OPC-41061)
化学式: C26H25ClN2O3 (448.15536099999997)
中文名称: 托伐普坦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C(C1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2C)C)(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O
InChI: InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
描述信息
C - Cardiovascular system > C03 - Diuretics > C03X - Other diuretics > C03XA - Vasopressin antagonists
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist
D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists
D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:32246
- PubChem: 216237
- ChEMBL: CHEMBL344159
- MeSH: Tolvaptan
- CAS: 150683-30-0
- MoNA: CCMSLIB00000078524
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Cong Yin, Juan Li, Lin Yuan. Comment on: Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis.
Clinical cardiology.
2023 05; 46(5):584. doi:
10.1002/clc.23994. [PMID: 36864618] - Shunta Akutsu, Yasuaki Mino, Takafumi Naito, Kohei Hoshikawa, Masao Saotome, Yuichiro Maekawa, Junichi Kawakami. Stereoselective interaction of tolvaptan with amiodarone under racemic metabolic impact by CYP3A5 genotypes in heart failure patients.
European journal of clinical pharmacology.
2022 Aug; 78(8):1311-1320. doi:
10.1007/s00228-022-03341-y. [PMID: 35604424] - Irene Capelli, Francesca Iacovella, Laura Ghedini, Valeria Aiello, Angelodaniele Napoletano, Lorenzo Marconi, Pierluigi Viale, Marco Masina, Gaetano LA Manna. A Case Report of Tolvaptan Therapy for ADPKD Patients With COVID-19. The Need for Appropriate Counselling for Temporary Drug Discontinuation.
In vivo (Athens, Greece).
2022 Jul; 36(4):1994-1997. doi:
10.21873/invivo.12924. [PMID: 35738624] - Jitendra Meena, Pankaj Hari, Aditi Sinha, Arvind Bagga. Efficacy and Safety of Combination Therapy with Tolvaptan and Furosemide in Children with Nephrotic Syndrome and Refractory Edema: A Prospective Interventional Study.
Indian journal of pediatrics.
2022 07; 89(7):699-705. doi:
10.1007/s12098-021-03988-y. [PMID: 35080742] - Tsutomu Murakami, Norihito Nakamura, Makoto Natsumeda, Shingo Matsumoto, Katsuaki Sakai, Yohei Ohno, Gaku Nakazawa, Norihiko Shinozaki, Yuji Ikari. Impact of tolvaptan on improvement of tricuspid regurgitation and right ventricular dimension in patients with right-sided heart failure.
Heart and vessels.
2022 Jul; 37(7):1153-1161. doi:
10.1007/s00380-021-02014-7. [PMID: 35050407] - Satoshi Kidoguchi, Kento Kitada, Yoshihide Fujisawa, Daisuke Nakano, Takashi Yokoo, Jens Titze, Akira Nishiyama. Tolvaptan induces body fluid loss and subsequent water conservation in normal rats.
Journal of pharmacological sciences.
2022 Jul; 149(3):115-123. doi:
10.1016/j.jphs.2022.04.008. [PMID: 35641024] - Naoko Shimoda, Mariko Ikeda, Tomohiro Yan, Sayuri Kawasaki, Akio Hirama, Tetsuya Kashiwagi, Yukinao Sakai. Long-Term Benefits of Treatment with Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease.
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
2022 Jun; 89(3):287-294. doi:
10.1272/jnms.jnms.2022_89-303. [PMID: 34526469] - Koichiro Kinugawa, Eisuke Nakata, Takahiro Hirano, Seongryul Kim. Tolerability of the Intravenously Administered Tolvaptan Prodrug, OPC-61815, in Patients With Congestive Heart Failure Who Have Difficulty With, or Are Incapable of, Oral Intake (TRITON-HF) - A Phase III, Multicenter, Open-Label Trial.
Circulation journal : official journal of the Japanese Circulation Society.
2022 Jun; 86(7):1068-1078. doi:
10.1253/circj.cj-21-0926. [PMID: 35264514] - Irene Cirella, Valentina di Vico, Matteo Rigato, Beatrice Bugnotto, Paola Baldini Anastasio, Daniela Campo, Gianni Carraro, Lorenzo A Calò. [Tolvaptan in ADPKD patients at the University of Padova Nephrology Unit: impact on quality of life, efficacy and safety].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2022 Jun; 39(3):. doi:
NULL. [PMID: 35819042] - Tao-Cheng Wu, Wei-Hung Chang, Hsin-Ying Lu, Chun-Che Shih. Tolvaptan reduces angiotensin II-induced experimental abdominal aortic aneurysm and dissection.
Vascular pharmacology.
2022 06; 144(?):106973. doi:
10.1016/j.vph.2022.106973. [PMID: 35227907] - Taro Akihisa, Hiroshi Kataoka, Shiho Makabe, Shun Manabe, Rie Yoshida, Yusuke Ushio, Masayo Sato, Ken Tsuchiya, Toshio Mochizuki, Kosaku Nitta. Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease.
Clinical and experimental nephrology.
2022 Jun; 26(6):540-551. doi:
10.1007/s10157-022-02192-2. [PMID: 35165806] - Nastaran Daneshgar, Peir-In Liang, Renny S Lan, McKenna M Horstmann, Lindsay Pack, Gourav Bhardwaj, Christie M Penniman, Brian T O'Neill, Dao-Fu Dai. Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations.
Kidney international.
2022 05; 101(5):906-911. doi:
10.1016/j.kint.2021.12.006. [PMID: 34953771] - Roman-Ulrich Müller, A Lianne Messchendorp, Henrik Birn, Giovambattista Capasso, Emilie Cornec-Le Gall, Olivier Devuyst, Albertien van Eerde, Patrick Guirchoun, Tess Harris, Ewout J Hoorn, Nine V A M Knoers, Uwe Korst, Djalila Mekahli, Yannick Le Meur, Tom Nijenhuis, Albert C M Ong, John A Sayer, Franz Schaefer, Aude Servais, Vladimir Tesar, Roser Torra, Stephen B Walsh, Ron T Gansevoort. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2022 04; 37(5):825-839. doi:
10.1093/ndt/gfab312. [PMID: 35134221] - Matteo Rigato, Gianni Carraro, Irene Cirella, Silvia Dian, Valentina Di Vico, Verdiana Ravarotto, Giovanni Bertoldi, Lorenzo A Calò. [Reduced oxidative stress in ADPKD patients treated with tolvaptan].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2022 Apr; 39(2):. doi:
. [PMID: 35470999] - Annabelle M Warren, Mathis Grossmann, Rudolf Hoermann, Jeffrey D Zajac, Nicholas Russell. Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial.
Trials.
2022 Apr; 23(1):335. doi:
10.1186/s13063-022-06237-5. [PMID: 35449020] - Bart J Kramers, Iris W Koorevaar, Maatje D A van Gastel, Harry van Goor, Kenneth R Hallows, Hiddo L Heerspink, Hui Li, Wouter N Leonhard, Dorien J M Peters, Jiedong Qiu, Daan J Touw, Ron T Gansevoort, Esther Meijer. Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
Clinical journal of the American Society of Nephrology : CJASN.
2022 04; 17(4):507-517. doi:
10.2215/cjn.11260821. [PMID: 35314480] - Naoki Sato, Shingo Uno, Yumiko Yamasaki, Takahiro Hirano, Seongryul Kim. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure - A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial.
Circulation journal : official journal of the Japanese Circulation Society.
2022 03; 86(4):699-708. doi:
10.1253/circj.cj-21-0430. [PMID: 34511586] - Jana Reiterová, Vladimír Tesař. Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment.
International journal of molecular sciences.
2022 Mar; 23(6):. doi:
10.3390/ijms23063317. [PMID: 35328738] - Koutatsu Shimozono, Yoshihiro Fukumoto. Effectiveness and Safety of Tolvaptan in Patients with Aortic Stenosis.
The Kurume medical journal.
2022 Mar; 67(1):11-16. doi:
10.2739/kurumemedj.ms671001. [PMID: 34840201] - Ivana Capuano, Pasquale Buonanno, Eleonora Riccio, Manuela Rizzo, Antonio Pisani. Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature.
Clinical nephrology.
2022 Mar; 97(3):131-140. doi:
10.5414/cn110510. [PMID: 34846296] - E Cuka, M Vespa, G Joli, P Manunta, T M Sciarrone Alibrandi. Tolvaptan-induced remission of primary palmar hyperhidrosis in a patient with ADPKD: a serendipitous finding.
Journal of nephrology.
2022 Mar; 35(2):671-674. doi:
10.1007/s40620-021-00973-8. [PMID: 33555573] - Ivana Capuano, Pasquale Buonanno, Eleonora Riccio, Maria Amicone, Antonio Pisani. Therapeutic advances in ADPKD: the future awaits.
Journal of nephrology.
2022 Mar; 35(2):397-415. doi:
10.1007/s40620-021-01062-6. [PMID: 34009558] - Leona Osawa, Hiroyuki Nakanishi, Masayuki Kurosaki, Sakura Kirino, Kento Inada, Koji Yamashita, Yuka Hayakawa, Shuhei Sekiguchi, Wan Wang, Mao Okada, Mayu Higuchi, Yasuyuki Komiyama, Kenta Takaura, Hitomi Takada, Shun Kaneko, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Kaoru Tsuchiya, Jun Itakura, Yuka Takahashi, Nobuyuki Enomoto, Namiki Izumi. Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan.
Digestive diseases (Basel, Switzerland).
2022; 40(4):479-488. doi:
10.1159/000518099. [PMID: 34348262] - Chunyang Xu, Xu Huang, Gaoliang Yan, Dong Wang, Meijuan Hu, Chengchun Tang. Tolvaptan Improves Contrast-Induced Acute Kidney Injury.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
2022; 2022(?):7435292. doi:
10.1155/2022/7435292. [PMID: 35173798] - Yoshihisa Yamada, Hiroyuki Fujiki, Hiroshi Mizuguchi, Yukinobu Takeshita, Katsuji Hattori, Koji Ohmoto, Miki Aihara, Keisuke Nagano, Yoshimasa Isakari, Miho Yamamoto, Yoshitaka Yamamura. [Tolvaptan, a vasopressin V2 receptor antagonist, is the world's first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
2022; 157(4):254-260. doi:
10.1254/fpj.22006. [PMID: 35781456] - Hiroki Mizuno, Akinari Sekine, Tatsuya Suwabe, Daisuke Ikuma, Masayuki Yamanouchi, Eiko Hasegawa, Naoki Sawa, Yoshifumi Ubara, Junichi Hoshino. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
PloS one.
2022; 17(2):e0264065. doi:
10.1371/journal.pone.0264065. [PMID: 35176098] - Mark Thomas, Pedro Henrique Franca Gois, Belinda E Butcher, Michelle H T Ta, Greg W Van Wyk. Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® dataset.
BMC nephrology.
2021 12; 22(1):400. doi:
10.1186/s12882-021-02607-4. [PMID: 34856944] - Alvin Estilo, Linda McCormick, Mirza Rahman. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
Advances in therapy.
2021 12; 38(12):5721-5736. doi:
10.1007/s12325-021-01947-9. [PMID: 34693505] - Tatsufumi Oka, Takayuki Hamano, Tomohito Ohtani, Yohei Doi, Karin Shimada, Ayumi Matsumoto, Satoshi Yamaguchi, Nobuhiro Hashimoto, Masamitsu Senda, Yusuke Sakaguchi, Isao Matsui, Kei Nakamoto, Fusako Sera, Shungo Hikoso, Yasushi Sakata, Yoshitaka Isaka. Renoprotection by long-term low-dose tolvaptan in patients with heart failure and hyponatremia.
ESC heart failure.
2021 12; 8(6):4904-4914. doi:
10.1002/ehf2.13507. [PMID: 34554640] - Michitaka Imai, Toru Ishikawa, Yuichi Kojima, Motoi Azumi, Yujiro Nozawa, Tomoe Sano, Akito Iwanaga, Terasu Honma, Toshiaki Yoshida. Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma.
European journal of gastroenterology & hepatology.
2021 12; 33(1S Suppl 1):e161-e166. doi:
10.1097/meg.0000000000001985. [PMID: 33196517] - Vera Christine Wulfmeyer, Roland Schmitt. [What is evidence-based in the treatment of autosomal dominant polycystic kidney disease?].
Der Internist.
2021 Dec; 62(12):1259-1268. doi:
10.1007/s00108-021-01199-3. [PMID: 34713320] - Emma T B Olesen, Robert A Fenton. Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases.
Nature reviews. Nephrology.
2021 11; 17(11):765-781. doi:
10.1038/s41581-021-00447-x. [PMID: 34211154] - Toshio Mochizuki, Satoru Muto, Masateru Miyake, Toshiki Tanaka, Wenchyi Wang. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
Clinical and experimental nephrology.
2021 Nov; 25(11):1231-1239. doi:
10.1007/s10157-021-02100-0. [PMID: 34228250] - Mari Saimiya, Yoshitsugu Kaku, Manao Nishimura. Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome.
CEN case reports.
2021 11; 10(4):523-526. doi:
10.1007/s13730-021-00601-1. [PMID: 33904139] - Anna Giuliani, Davide Marturano, Valentina Corradi, Carlotta Caprara, Matteo Rigato, Matteo Marcello, Fiorella Gastaldon, Claudio Ronco, Monica Zanella. [Slowing progression of chronic kidney disease in polycistic kidney disease patients with tolvaptan: from guidelines to clinical practice].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2021 Oct; 38(5):. doi:
NULL. [PMID: 34713645] - Yasuhiro Futamura, Hirotaka Watanuki, Masaho Okada, Kayo Sugiyama, Katsuhiko Matsuyama. The Efficacy and Renal Protective Effect of Tolvaptan in Chronic Kidney Disease Patients after Open-Heart Surgery.
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
2021 Oct; 27(5):317-321. doi:
10.5761/atcs.oa.20-00364. [PMID: 34053960] - Yasuhiro Hitomi, Yuji Nagatomo, Midori Yukino, Yusuke Yumita, Kazuki Kagami, Risako Yasuda, Takumi Toya, Takayuki Namba, Nobuyuki Masaki, Hirotaka Yada, Takeshi Adachi. Characterization of tolvaptan response and its impact on the outcome for patients with heart failure.
Journal of cardiology.
2021 10; 78(4):285-293. doi:
10.1016/j.jjcc.2021.04.014. [PMID: 34039465] - Takashi Hatano, Katsuhisa Endo. Short-term changes in micturition patterns with tolvaptan treatment for autosomal dominant polycystic kidney disease.
Asian journal of surgery.
2021 Oct; 44(10):1332-1333. doi:
10.1016/j.asjsur.2021.06.050. [PMID: 34376362] - Shungo Imai, Kenji Momo, Hitoshi Kashiwagi, Yuki Sato, Takayuki Miyai, Mitsuru Sugawara, Yoh Takekuma. A cross-sectional survey of hospitalization and blood tests implementation status in patients who received tolvaptan under 75 years of age using a Japanese claims database.
Expert opinion on drug safety.
2021 Oct; 20(10):1257-1266. doi:
10.1080/14740338.2021.1951219. [PMID: 34225550] - Shigeki Yokoyama, Teruhiko Imamura, Shigeyuki Yamashita, Toshio Doi, Kazuaki Fukahara, Naoki Yoshimura, Koichiro Kinugawa. Peak Lag Between Plasma Vasopressin and Urine Aquaporin-2 Following Cardiac Surgery.
International heart journal.
2021 Sep; 62(5):1057-1061. doi:
10.1536/ihj.21-301. [PMID: 34544990] - Kiyotaka Uchiyama, Chigusa Kitayama, Akane Yanai, Yoshitaka Ishibashi. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.
Scientific reports.
2021 09; 11(1):17666. doi:
10.1038/s41598-021-97113-w. [PMID: 34480075] - Satoru Muto, Tadashi Okada, Yoshiyuki Shibasaki, Tatsuki Ibuki, Shigeo Horie. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
Clinical and experimental nephrology.
2021 Sep; 25(9):1003-1010. doi:
10.1007/s10157-021-02083-y. [PMID: 34089122] - Fouad T Chebib, Vicente E Torres. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 08; 78(2):282-292. doi:
10.1053/j.ajkd.2020.12.020. [PMID: 33705818] - Taro Akihisa, Shun Manabe, Hiroshi Kataoka, Shiho Makabe, Rie Yoshida, Yusuke Ushio, Kentaro Watanabe, Masayo Sato, Ken Tsuchiya, Toshio Mochizuki, Kosaku Nitta. Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease.
Kidney360.
2021 07; 2(7):1148-1151. doi:
10.34067/kid.0007342020. [PMID: 35368344] - Susan E Shoaf, Patricia Bricmont, Jennifer Repella Gordon. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
Clinical and translational science.
2021 07; 14(4):1535-1542. doi:
10.1111/cts.13017. [PMID: 33742787] - Daishi Hirano, Saori Miwa, Daisuke Kakegawa, Chisato Umeda, Yoichi Takemasa, Ai Tokunaga, Kawakami Yuhei, Akira Ito. Impact of acute kidney injury in patients prescribed angiotensin-converting enzyme inhibitors over the first two years of life.
Pediatric nephrology (Berlin, Germany).
2021 07; 36(7):1907-1914. doi:
10.1007/s00467-021-04920-4. [PMID: 33462699] - Taylor Richards, Kavindiya Modarage, Soniya A Malik, Paraskevi Goggolidou. The cellular pathways and potential therapeutics of Polycystic Kidney Disease.
Biochemical Society transactions.
2021 06; 49(3):1171-1188. doi:
10.1042/bst20200757. [PMID: 34156429] - Martin Kieninger, Christina Kerscher, Elisabeth Bründl, Sylvia Bele, Martin Proescholdt, Florian Zeman, Bernhard Graf, Nils-Ole Schmidt, Karl-Michael Schebesch. Acute hyponatremia after aneurysmal subarachnoid hemorrhage: Frequency, treatment, and outcome.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.
2021 Jun; 88(?):237-242. doi:
10.1016/j.jocn.2021.04.004. [PMID: 33992191] - Kristen L Nowak, Cortney Steele, Berenice Gitomer, Wenchyi Wang, John Ouyang, Michel B Chonchol. Overweight and Obesity and Progression of ADPKD.
Clinical journal of the American Society of Nephrology : CJASN.
2021 06; 16(6):908-915. doi:
10.2215/cjn.16871020. [PMID: 34117082] - Yusuke Morita, Akihiro Endo, Yuzo Kagawa, Kazuto Yamaguchi, Hirotomo Sato, Takeshi Ouchi, Nobuhide Watanabe, Kazuaki Tanabe. Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure.
Heart and vessels.
2021 Jun; 36(6):836-843. doi:
10.1007/s00380-020-01753-3. [PMID: 33527152] - Hiroaki Ogata, Naoko Shimofurutani, Tadashi Okada, Hisashi Nagamoto, Tadao Akizawa. Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2021 05; 36(6):1088-1097. doi:
10.1093/ndt/gfaa148. [PMID: 32901255] - Shigeo Horie, Satoru Muto, Haruna Kawano, Tadashi Okada, Yoshiyuki Shibasaki, Koji Nakajima, Tatsuki Ibuki. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Clinical and experimental nephrology.
2021 May; 25(5):467-478. doi:
10.1007/s10157-020-02009-0. [PMID: 33471240] - Miho Akabane, Yasuo Ishii, Yuki Nakamura, Takayoshi Yokoyama, Katsuyuki Miki. Usefulness of Tolvaptan for the Postoperative Control After Kidney Transplantation in a Patient With Cardiac Hypofunction: A Case Report.
Transplantation proceedings.
2021 May; 53(4):1288-1291. doi:
10.1016/j.transproceed.2021.03.018. [PMID: 33865611] - Takuro Kojima, Azusa Kanai, Shigeki Yoshiba, Toshiki Kobayashi, Naokata Sumitomo. Efficacy and safety of tolvaptan after pediatric congenital heart disease surgery.
Heart and vessels.
2021 May; 36(5):717-723. doi:
10.1007/s00380-020-01743-5. [PMID: 33388911] - Toshihiro Kudo, Yoshiyuki Murai, Yoshitsugu Kojima, Kenji Uehara, Taroh Satoh. Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study.
Japanese journal of clinical oncology.
2021 Mar; 51(3):354-362. doi:
10.1093/jjco/hyaa196. [PMID: 33173939] - Tomofumi Moriyama, Yosuke Nakayama, Mikiko Soejima, Yunosuke Yokota, Kanji Ota, Sakuya Ito, Goh Kodama, Nao Nakamura, Yuka Kurokawa, Junko Yano, Utako Ueda, Yoshimi Takamiya, Yusuke Kaida, Takuma Hazama, Ryo Shibata, Yoshiro Koda, Kei Fukami. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
Clinical and experimental nephrology.
2021 Mar; 25(3):251-260. doi:
10.1007/s10157-020-01988-4. [PMID: 33141305] - Rupesh Raina, Ronith Chakraborty, Meredith E DeCoy, Timothy Kline. Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression.
Pediatric research.
2021 03; 89(4):894-899. doi:
10.1038/s41390-020-0942-2. [PMID: 32392574] - Olivier Bonny, Pierre-Yves Martin, Fabien Stucker. [Clinical use of tolvaptan: a 2021 review].
Revue medicale suisse.
2021 Feb; 17(727):399-404. doi:
. [PMID: 33625806] - James J Beaudoin, William J Brock, Paul B Watkins, Kim L R Brouwer. Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity.
Clinical pharmacology and therapeutics.
2021 02; 109(2):433-442. doi:
10.1002/cpt.2007. [PMID: 32748396] - Kota Kakeshita, Tsutomu Koike, Teruhiko Imamura, Hayato Fujioka, Hidenori Yamazaki, Koichiro Kinugawa. Expression of aquaporin-2 in the collecting duct and responses to tolvaptan.
CEN case reports.
2021 02; 10(1):69-73. doi:
10.1007/s13730-020-00518-1. [PMID: 32779125] - Hiroshi Arima, Koichi Goto, Tomohisa Motozawa, Makoto Mouri, Ryo Watanabe, Takahiro Hirano, San-E Ishikawa. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
Endocrine journal.
2021 Jan; 68(1):17-29. doi:
10.1507/endocrj.ej20-0216. [PMID: 32863282] - Adrien Flahault, Pierre-Emmanuel Girault-Sotias, Mathilde Keck, Rodrigo Alvear-Perez, Nadia De Mota, Lucie Estéoulle, Sridévi M Ramanoudjame, Xavier Iturrioz, Dominique Bonnet, Catherine Llorens-Cortes. A metabolically stable apelin-17 analog decreases AVP-induced antidiuresis and improves hyponatremia.
Nature communications.
2021 01; 12(1):305. doi:
10.1038/s41467-020-20560-y. [PMID: 33436646] - Sean Hammond, Andrew Gibson, Kanoot Jaruthamsophon, Sharin Roth, Merrie Mosedale, Dean J Naisbitt. Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite.
Toxicological sciences : an official journal of the Society of Toxicology.
2021 01; 179(1):95-107. doi:
10.1093/toxsci/kfaa157. [PMID: 33078835] - Y Suzuki, A Naganuma, T Hoshino, T Hatanaka, T Ueno, M Namikawa, D Takizawa, H Arai, H Suzuki, H Takagi, H Tojima, Y Yamazaki, K Sato, S Kakizaki, T Uraoka. Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study.
Acta gastro-enterologica Belgica.
2021 Jan; 84(1):57-63. doi:
10.51821/84.1.357. [PMID: 33639694] - Ryuta Shigefuku, Motoh Iwasa, Akiko Eguchi, Mina Tempaku, Yasuyuki Tamai, Tatsuya Suzuki, Yoshiyuki Takei. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
Internal medicine (Tokyo, Japan).
2021; 60(21):3359-3368. doi:
10.2169/internalmedicine.7291-21. [PMID: 34719623] - Jonathan Urbach, Steven R Goldsmith. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
Therapeutic advances in cardiovascular disease.
2021 Jan; 15(?):1753944720977741. doi:
10.1177/1753944720977741. [PMID: 33435837] - Nobukiyo Tanaka, Kazuhiro Dan, Takuya Maeda, Hiroki Ishihara, Masanori Teramura, Kei Ichihashi, Yuya Takahashi, Daichi Tsuzura, Akira Shinoda, Masato Fujii, Hisashi Okada, Tomohiko Teramoto. Clinical Effects of Early and Short-Term Tolvaptan Administration in Patients Hospitalized for Acute Decompensated Heart Failure.
Cardiology.
2021 ; 146(6):739-747. doi:
10.1159/000518732. [PMID: 34348260] - Rie Shinoda, Yasutaka Shinoda, Takayuki Mori, Tomoaki Yoshimura. [Retrospective Observational Study on Predictors of Body Weight and BNP Teduction in Cases of Tolvaptan Induction for Heart Failure].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
2021; 141(2):281-288. doi:
10.1248/yakushi.20-00221. [PMID: 33518649] - Yunjin Bai, Yin Tang, Jiahao Wang, Xiaoming Wang, Zhenghao Wang, Dehong Cao, Ping Han, Jia Wang. Tolvaptan treatment of cystine urolithiasis in a mouse model of cystinuria.
World journal of urology.
2021 Jan; 39(1):263-269. doi:
10.1007/s00345-020-03166-3. [PMID: 32189089] - Yasunari Hiramine, Hirofumi Uto, Seiichi Mawatari, Shuji Kanmura, Yasushi Imamura, Takuya Hiwaki, Akiko Saishoji, Manei Oku, Koichi Tokushige, Shigeho Maenohara, Akio Ido. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
Journal of gastroenterology.
2021 Jan; 56(1):54-66. doi:
10.1007/s00535-020-01727-2. [PMID: 32959093] - Silvia Lai, Marco Mangiulli, Adolfo M Perrotta, Antonietta Gigante, Ludovica Napoleoni, Elena Cipolloni, Anna P Mitterhofer, Maria L Gasperini, Maurizio Muscaritoli, Rosario Cianci, Antonello Giovannetti, Fabiana Falco, Daniela Mastroluca, Sandro Mazzaferro. Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study.
Current vascular pharmacology.
2021; 19(5):556-564. doi:
10.2174/1570161118999200918094809. [PMID: 32957887] - Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Ronald D Perrone, Jennifer Lee, Molly E Hoke, Alvin Estilo, Olga Sergeyeva. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Clinical journal of the American Society of Nephrology : CJASN.
2020 12; 16(1):48-58. doi:
10.2215/cjn.10250620. [PMID: 33376102] - Dipal M Patel, Neera K Dahl. Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?.
Clinical journal of the American Society of Nephrology : CJASN.
2020 12; 16(1):3-5. doi:
10.2215/cjn.17981120. [PMID: 33376103] - Masaaki Takamura, Akira Sakamaki, Yoshihisa Arao, Toru Setsu, Hiroteru Kamimura, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai. Daily Monitoring of Serum Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein Is Useful for Predicting Therapeutic Effect of Tolvaptan in Cirrhotic Ascites.
The Tohoku journal of experimental medicine.
2020 12; 252(4):287-296. doi:
10.1620/tjem.252.287. [PMID: 33208569] - Masato Nakai, Goki Suda, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Naoki Kawagishi, Masatsugu Ohara, Machiko Umemura, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto. Durable response without recurrence to Tolvaptan improves long-term survival.
Journal of gastroenterology.
2020 Dec; 55(12):1150-1161. doi:
10.1007/s00535-020-01721-8. [PMID: 32851487] - A Dachy, L Collard, J M Krzesinski, M C Seghaye, M S Ghuysen, D Mekahli, F Jouret. [Autosomal dominant polycystic kidney disease : a pediatric perspective].
Revue medicale de Liege.
2020 Dec; 75(12):775-780. doi:
NULL. [PMID: 33331700] - Jieting Tang, Yongfeng Wang, Tao Han, Qing Mao, Jun Cheng, Huiguo Ding, Jia Shang, Qin Zhang, Junqi Niu, Feng Ji, Chengwei Chen, Jidong Jia, Xiangjun Jiang, Nonghua Lv, Yueqiu Gao, Zhenghua Wang, Zhong Wei, Yingxuan Chen, Minde Zeng, Yimin Mao. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.
BMC gastroenterology.
2020 Nov; 20(1):391. doi:
10.1186/s12876-020-01536-0. [PMID: 33213378] - Andrew Gibson, Sean Hammond, Kanoot Jaruthamsophon, Sharin Roth, Merrie Mosedale, Dean J Naisbitt. Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury.
Chemical research in toxicology.
2020 11; 33(11):2745-2748. doi:
10.1021/acs.chemrestox.0c00328. [PMID: 33085478] - Koji Takagi, Naoki Sato, Shiro Ishihara, Hayano Iha, Noriyuki Kobayashi, Yusuke Ito, Tsuyoshi Nohara, Satoru Ohkuma, Tatsuya Mitsuishi, Atsushi Ishizuka, Shota Shigihara, Michiko Sone, Kenji Nakama, Hideo Tokuyama, Toshiya Omote, Arifumi Kikuchi, Shunichi Nakamura, Eisei Yamamoto, Masahiro Ishikawa, Kenichi Amitani, Naoto Takahashi, Yuji Maruyama, Hajime Imura, Wataru Shimizu. Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.
Journal of cardiology.
2020 11; 76(5):499-505. doi:
10.1016/j.jjcc.2020.05.012. [PMID: 32665162] - Joseph J Alukal, Savio John, Paul J Thuluvath. Hyponatremia in Cirrhosis: An Update.
The American journal of gastroenterology.
2020 11; 115(11):1775-1785. doi:
10.14309/ajg.0000000000000786. [PMID: 33156095] - Dean G Assimos. Re: Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
The Journal of urology.
2020 11; 204(5):1090-1091. doi:
10.1097/ju.0000000000001258.01. [PMID: 32820999] - Hidetada Fukuoka, Koichi Tachibana, Yukinori Shinoda, Tomoko Minamisaka, Hirooki Inui, Keisuke Ueno, Soki Inoue, Kentaro Mine, Kumpei Ueda, Shiro Hoshida. Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure.
BMC cardiovascular disorders.
2020 10; 20(1):467. doi:
10.1186/s12872-020-01751-3. [PMID: 33121430] - Jingyi Hu, Qianli Wan, Yue Zhang, Jun Zhou, Miaomiao Li, Li Jiang, Fang Yuan. Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial.
BMC cardiovascular disorders.
2020 10; 20(1):447. doi:
10.1186/s12872-020-01733-5. [PMID: 33054727] - Federica Prosperi, Yoko Suzumoto, Pierluigi Marzuillo, Vincenzo Costanzo, Sabina Jelen, Anna Iervolino, Stefano Guarino, Angela La Manna, Emanuele Miraglia Del Giudice, Alessandra F Perna, Miriam Zacchia, Emmanuelle Cordat, Giovambattista Capasso, Francesco Trepiccione. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
Scientific reports.
2020 10; 10(1):16383. doi:
10.1038/s41598-020-73089-x. [PMID: 33009446] - Caleb P Nelson, Michael P Kurtz, Alyssia Venna, Bartley G Cilento, Michelle A Baum. Pharmacological Dilutional Therapy Using the Vasopressin Antagonist Tolvaptan for Young Patients With Cystinuria: A Pilot Investigation.
Urology.
2020 10; 144(?):65-70. doi:
10.1016/j.urology.2020.07.002. [PMID: 32683063] - Mohamed El-Shabrawy, Amal Mishriki, Hisham Attia, Basma Emad Aboulhoda, Mohamed Emam, Hanaa Wanas. Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models.
Pharmacology research & perspectives.
2020 10; 8(5):e00659. doi:
10.1002/prp2.659. [PMID: 32996719] - Masayuki Saito, Tohru Maeda, Toshihiko Ichihara, Takahiro Iwao, Tadashi Suzuki. [The Effect of Increased Free Concentrations of Warfarin Due to Protein-binding Substitution in a Combination of Tolvaptan on the PT-INR].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
2020 Oct; 140(10):1269-1274. doi:
10.1248/yakushi.20-00016. [PMID: 32684555] - I Agraz-Pamplona, M Larrosa-Garcia, R P Bury-Macias, D Serón-Micas, J B Montoro-Ronsano. Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD).
European journal of clinical pharmacology.
2020 Oct; 76(10):1473-1475. doi:
10.1007/s00228-020-02906-z. [PMID: 32514744] - Biruh T Workeneh, Kenar D Jhaveri, Helbert Rondon-Berrios. Hyponatremia in the cancer patient.
Kidney international.
2020 10; 98(4):870-882. doi:
10.1016/j.kint.2020.05.015. [PMID: 32497528] - Reiko Inoue, Hiroshi Nishi, Daisuke Inoue, Kenjiro Honda, Masaomi Nangaku. Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease.
Kidney360.
2020 08; 1(8):740-745. doi:
10.34067/kid.0002262020. [PMID: 35372950] - Esther Meijer, Ron T Gansevoort. Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability.
Kidney international.
2020 08; 98(2):289-293. doi:
10.1016/j.kint.2020.03.023. [PMID: 32709290] - Brad H Rovin. A tolvaptan skeptic repents.
Kidney international.
2020 08; 98(2):293. doi:
10.1016/j.kint.2020.04.005. [PMID: 32709291] - Hiromi Kin, Koichiro Matsumura, Yoshihiro Yamamoto, Kenichi Fujii, Munemitsu Otagaki, Hiroki Takahashi, Haengnam Park, Kei Yoshioka, Mitsuru Yokoi, Tetsuro Sugiura, Ichiro Shiojima. Renoprotective effect of tolvaptan in patients with new-onset acute heart failure.
ESC heart failure.
2020 08; 7(4):1764-1770. doi:
10.1002/ehf2.12738. [PMID: 32383323] - Tien M H Ng, Luanda P Grazette, Michael W Fong, Andrew J Yoon, Mimi Lou, Allen Kuo, Rani Y Upadhyay, Emily E Han, Anilkumar Mehra, Uri Elkayam. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).
ESC heart failure.
2020 08; 7(4):1927-1934. doi:
10.1002/ehf2.12783. [PMID: 32543020] - Isao Sakaida, Shuji Terai, Masayuki Kurosaki, Mitsuru Okada, Takahiro Hirano, Yasuhiko Fukuta. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
Journal of gastroenterology.
2020 Aug; 55(8):800-810. doi:
10.1007/s00535-020-01691-x. [PMID: 32388692] - Craig E Gordon, Ronald D Perrone. Tolvaptan or transplant: why wait?.
Kidney international.
2020 08; 98(2):286-289. doi:
10.1016/j.kint.2020.03.022. [PMID: 32709289] - Covadonga López Del Moral Cuesta, Gema Fernández Fresnedo, Luis Martín Penagos. Clinical experience with tolvaptan in patients with polycystic kidney disease.
Medicina clinica.
2020 07; 155(2):83-84. doi:
10.1016/j.medcli.2019.03.011. [PMID: 31130311] - Jean-Daniel Delbet, Cyrielle Parmentier, Tim Ulinski. Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome.
Pediatric nephrology (Berlin, Germany).
2020 07; 35(7):1347-1350. doi:
10.1007/s00467-020-04530-6. [PMID: 32232633] - Ewout J Hoorn, Robert Zietse. ADPKD, Tolvaptan, and Nephrolithiasis Risk.
Clinical journal of the American Society of Nephrology : CJASN.
2020 07; 15(7):923-925. doi:
10.2215/cjn.07610520. [PMID: 32527947]